Home Compare HIK.L vs SN.L
Stock Comparison · Structural lead, mixed market

Hikma Pharmaceuticals vs Smith & Nephew: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Smith & Nephew carrying a narrow edge on valuation. Hikma Pharmaceuticals still has the edge on valuation, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.

Updated 2026-07-05

Valuation points more clearly toward Hikma Pharmaceuticals PLC, even if the broader score still leans toward Smith & Nephew plc.

Trajectory Similarity
0.72
Similar
Peer-set rank: #10
within Hikma Pharmaceuticals PLC's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

The pair sits on a clearly comparable long-term path, though it is not a near-twin match.

The match is driven mainly by capital structure and margin consistency.

Similarity drivers
capital structuremargin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
HIK.L
Hikma Pharmaceuticals PLC
58
Peer-Score
Signal qualityMedium
Peer basis: STOXX 600
vs
SN.L
Smith & Nephew plc
61
Peer-Score
Signal qualityMedium
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: HIK.L vs SN.L Profitability 45 62 Stability 32 47 Valuation 86 59 Growth 63 78 HIK.L SN.L
Gap Ranking
#1 Valuation +27
#2 Profitability +17
#3 Growth +15
#4 Stability +15
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for HIK.L and SN.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer HIK.LSN.L Relative valuation Structural strength

Smith & Nephew plc occupies the cheaper side of the setup map, although Hikma Pharmaceuticals PLC still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both rank well on valuation, but Hikma Pharmaceuticals PLC still holds a clear edge.
Profitability
On profitability, the edge still sits with Smith & Nephew plc, even though both profiles look solid.
Valuation — Dominant Gap
HIK.L
86
SN.L
59
Gap+27in favour of HIK.L

The main spread comes from a meaningfully cheaper peer-relative valuation.

What keeps the gap from being one-sided

Hikma Pharmaceuticals PLC still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

The lead is built on both valuation and profitability — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the HIK.L vs SN.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how HIK.L and SN.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.